Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Anaphylaxis Market’s Growth Trajectory From 2025 To 2034?
In previous years, the anaphylaxis market has witnessed robust growth. The market, which was valued at $3.24 billion in 2024, is predicted to escalate to $3.5 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. Factors that contributed to the expansion during the historic period include an increasing occurrence of food allergies, heightened awareness of anaphylaxis, development in healthcare infrastructure, improved diagnosis and management, and the widening accessibility of epinephrine auto-injectors.
The anaphylaxis market is projected to experience robust growth in the forthcoming years, escalating to$4.78 billion by 2029 with a compound annual growth rate (CAGR) of 8.1%. This growth during the predicted period can be credited to factors such as the surge in urbanization and shifts in lifestyle, an increasing number of anaphylactic cases, rising disposable income in developing markets, government investments in allergy research, and breakthroughs in emergency treatment delivery systems. Key trends for the forecast period encompass the escalating demand for auto-injectable epinephrine, implementation of digital health approaches in anaphylaxis management, heightened emphasis on product affordability, rising in preventive therapies and vaccines, and increased usage of biologics in allergy treatment.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21096&type=smp
Which Factors and External Forces Are Driving Demand in the Anaphylaxis Market?
The growth of the anaphylaxis market is anticipated to be fueled by the increasing instances of food allergies. These immune system reactions, which can range from mild to intense, are provoked by specific foods, and can cause life-threatening anaphylaxis. The upward trend in food allergies can be ascribed to factors like modifications in eating habits, environmental impacts, and greater consciousness and diagnosis. Intervention in the case of anaphylaxis is crucial to food allergy patients as it promptly mitigates severe allergic reactions, alleviates symptoms like swelling, breathlessness, and blood pressure drop, offering immediate stabilization and averting potentially lethal outcomes. It also provides patients with the necessary tools to respond quickly to future allergic episodes. As per data from the World Health Organization (WHO), a UN organization based in Switzerland, in September 2024, around 220 million people worldwide were afflicted by food allergies. It’s not uncommon for a single food item to contain multiple allergens and for an individual to be allergic to several types of food. Furthermore, according to a report by the Food Standards Agency (FSA), a non-ministerial department in the UK, titled Patterns and Prevalence of Adult Food Allergy (PAFA), published in May 2024, over 30% of adults reported adverse reactions to food, and about 6% of UK adults, amounting to roughly 2.4 million individuals, were clinically diagnosed with food allergies. Consequently, the increased incidence of food allergies is propelling the expansion of the anaphylaxis market.
Which Segments in the Anaphylaxis Offer the Most Growth?
The anaphylaxismarket covered in this report is segmented –
1) By Drug Class: Epinephrine; Steroids; Antihistamines; Beta-antagonists; Other Drug Class
2) By Route Of Administration: Parenteral; Oral; Other Routes Of Administration
3) By Application: Food Allergy; Pollen Allergy; Dust Mites Allergy; Other Applications
Subsegments:
1) By Epinephrine: Auto-injectors; Prefilled Syringes; Vials
2) By Steroids: Corticosteroids; Glucocorticoids; Mineralocorticoids
3) By Antihistamines: H1-receptor Antagonists; H2-receptor Antagonists
4) By Beta-antagonists: Selective Beta-blockers; Non-selective Beta-blockers
5) By Other Drug Class: Leukotriene Receptor Antagonists; Mast Cell Stabilizers
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21096&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Anaphylaxis Market?# Market?
North America was the largest region in the anaphylaxis market in 2024. The regions covered in the anaphylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theAnaphylaxis Market’s Growth?
Firms of great significance in the anaphylaxis market are zeroing in on the development of progressive epinephrine nasal sprays, designed for quicker and more effective drug administration in critical situations. The spray, a medical implement, delivers epinephrine, also known as adrenaline, through the nasal cavity, and is a treatment for serious allergies, including anaphylaxis. To illustrate, in August 2024, ARS Pharmaceuticals, a biotechnology business based in the US, announced that the US government agency Food and Drug Administration approved its product Neffy, an epinephrine nasal spray. This marked it as the inaugural and sole needle-less treatment option for type I allergies, inclusive of anaphylaxis. This innovative treatment method, in the form of a nasal spray, provides an alternative to traditional epinephrine autoinjectors, creating a possibly more convenient choice for emergency medical attention. Neffy’s goal is to increase patient adherence by removing the need for needles, while still allowing for immediate, crucial epinephrine delivery during severe allergic reactions.
View the full report here:
https://www.thebusinessresearchcompany.com/report/anaphylaxis-global-market-report
What Are the Key Elements That Define the Anaphylaxis Market?
Anaphylaxis is a severe, life-threatening allergic reaction that occurs rapidly, often resulting in difficulty breathing, swelling, and a drop in blood pressure, requiring immediate medical intervention. Management of anaphylaxis involves prompt administration of epinephrine, followed by monitoring in a healthcare setting to stabilize the patient and prevent further complications.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21096
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
